Guang-Xu Liu1, Yun-Cui Yu2, Xiang-Ping He3, Sheng-Nan Ren4, Xue-Dong Fang4, Fen Liu2, Yan He2. 1. Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityBeijing 100069, China; Beijing Municipal Key Laboratory of Clinical EpidemiologyBeijing 100069, China; Physical Examination Center, 731 Hospital, China Aerospace Science and Industry CorporationBeijing, China. 2. Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityBeijing 100069, China; Beijing Municipal Key Laboratory of Clinical EpidemiologyBeijing 100069, China. 3. Center of Prevention and Cure of Breast Diseases, Haidian Maternal & Child Health Hospital Beijing 100080, China. 4. Department of General Surgery, China-Japan Union Hospital of Jilin University Changchun 130021, Jilin, China.
Abstract
BACKGROUNDS: Expression of eag1 channel (Eag1) is associated with cell malignant transformation, tumor cell metastasis and poor prognosis of the patient. This study aimed at examining whether expression of the Eag1 associated with aggressive clinicopathological feature and the molecular subtype of breast cancer. MATERIALS AND METHODS: 109 patients who received breast cancer operation during January 2009 to December 2010 in Chinese-Japanese Friendship Hospital of Jilin University were recruited. We investigated the association of the Eag1 with clinicopathological features and molecular subtype of in triple negative breast cancer (TNBC) by univariate or multivariate analysis in a cross-section study. RESULTS: The positive rate of Eag1 was 18.5% higher in TNBC compared with non-triple negative breast cancer (Non-TNBC) (P = 0.012, OR = 2.83, 95% CI = 2.16-3.47). Compared with the Eag1 negative group, the expression of Eag1 was linked to the larger tumor size (P = 0.002), advanced TNM stage (P = 0.029), high proportion of positive lymph node (87.6% vs. 65%, P = 0.014) and invasive ductal carcinoma (91% vs. 75%, P = 0.046). CONCLUSIONS: The expression of Eag1 may be partially explained the aggressive behavior of TNBC in the breast cancer tissue.
BACKGROUNDS: Expression of eag1 channel (Eag1) is associated with cell malignant transformation, tumor cell metastasis and poor prognosis of the patient. This study aimed at examining whether expression of the Eag1 associated with aggressive clinicopathological feature and the molecular subtype of breast cancer. MATERIALS AND METHODS: 109 patients who received breast cancer operation during January 2009 to December 2010 in Chinese-Japanese Friendship Hospital of Jilin University were recruited. We investigated the association of the Eag1 with clinicopathological features and molecular subtype of in triple negative breast cancer (TNBC) by univariate or multivariate analysis in a cross-section study. RESULTS: The positive rate of Eag1 was 18.5% higher in TNBC compared with non-triple negative breast cancer (Non-TNBC) (P = 0.012, OR = 2.83, 95% CI = 2.16-3.47). Compared with the Eag1 negative group, the expression of Eag1 was linked to the larger tumor size (P = 0.002), advanced TNM stage (P = 0.029), high proportion of positive lymph node (87.6% vs. 65%, P = 0.014) and invasive ductal carcinoma (91% vs. 75%, P = 0.046). CONCLUSIONS: The expression of Eag1 may be partially explained the aggressive behavior of TNBC in the breast cancer tissue.
Entities:
Keywords:
Eag1 channel; association; clinicopathological features; triple negative breast cancer
Authors: Michael P DiGiovanna; David F Stern; Susan M Edgerton; Steve G Whalen; Dan Moore; Ann D Thor Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Stephan Patt; Katja Preussat; Christian Beetz; Robert Kraft; Michael Schrey; Rolf Kalff; Kristina Schönherr; Stefan H Heinemann Journal: Neurosci Lett Date: 2004-09-30 Impact factor: 3.046
Authors: Catherine Oakman; Marta Pestrin; Elena Zafarana; Egidia Cantisani; Angelo Di Leo Journal: Cancer Manag Res Date: 2010-01-07 Impact factor: 3.989
Authors: Bernhard Hemmerlein; Rüdiger M Weseloh; Fernanda Mello de Queiroz; Hendrik Knötgen; Araceli Sánchez; María E Rubio; Sabine Martin; Tessa Schliephacke; Marc Jenke; Walter Stühmer; Luis A Pardo Journal: Mol Cancer Date: 2006-10-05 Impact factor: 27.401